2.Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation.
Zachary SPIRITOS ; Parit MEKAROONKAMOL ; Bassel F EL-RAYES ; Seth D FORCE ; Steven A KEILIN ; Qiang CAI ; Field F WILLINGHAM
Clinical Endoscopy 2017;50(5):491-494
Esophageal cancer has a poor overall prognosis and is frequently diagnosed at a late stage. Conventional treatment for metastatic esophageal cancer involves chemotherapy and radiation. Local disease control plays a significant role in improving survival. Endoscopic spray cryotherapy is a novel modality that involves freezing and thawing to produce local ablation of malignant tissue via ischemic mechanisms. Spray cryotherapy has been shown to be effective, particularly for early T-stage, superficial esophageal adenocarcinomas. We present the case of a 72-year-old-male with locally recurrent stage IV esophageal adenocarcinoma and long-term survival of 7 years to date, with concurrent chemoradiation and serial cryoablation. He remains asymptomatic and continues to undergo chemotherapy and sequential cryoablation. The findings highlight the long-term safety and efficacy of cryotherapy in combination with chemoradiation, and suggest that cryoablation may have an additive role in the treatment of advanced stage esophageal adenocarcinoma.
Adenocarcinoma*
;
Cryosurgery*
;
Cryotherapy
;
Drug Therapy
;
Esophageal Neoplasms
;
Freezing
;
Prognosis
3.Clinical characteristics of digestive system cancers metastatic to the heart.
Jia Lin TANG ; Bo ZHANG ; Xing Yuan WANG ; Yan SONG ; Jian Ping XU ; Tao QU ; Yihebali CHI ; Jing HUANG
Chinese Journal of Oncology 2022;44(11):1229-1232
Objective: To investigate the clinical features of patients with cardiac metastases from digestive system tumors. Methods: This retrospective study collected and analyzed the medical records of patients with cardiac metastases from digestive system tumors who received treatments in the Cancer Hospital, Chinese Academy of Medical Sciences between January 1999 and January 2021. Kaplan-Meier method was used for survival analysis. Results: A total of 19 patients were identified. The primary tumors were esophageal squamous cell carcinoma (n=7), gastric or gastroesophageal junction adenocarcinoma (n=6), hepatobiliary cancers (n=3) and colorectal cancers (n=3). 16 patients had pericardial metastases, 2 patients had right atrium metastases, and 1 patient had left ventricle metastasis. The most common symptom was dyspnea, which was present in 8 cases. 7 patients received locoregional treatment, while 11 patients underwent systemic therapies. The median overall survival from diagnosis of primary cancer was 31.4 months, and the median overall survival time from diagnosis of cardiac metastasis was 4.7 months. Conclusion: Cardiac metastasis from digestive system tumors is associated with low incidence and a poor prognosis. Systemic treatment remains the cornerstone of management, while novel anti-tumor drugs may improve therapeutic efficacy.
Humans
;
Esophageal Neoplasms/pathology*
;
Retrospective Studies
;
Prognosis
;
Esophageal Squamous Cell Carcinoma
;
Digestive System Neoplasms/drug therapy*
;
Gastrointestinal Neoplasms
4.Research progress of identifying predictive biomarkers for induction therapy in esophageal cancer.
Chinese Journal of Gastrointestinal Surgery 2015;18(9):953-957
Surgery is still the major treatment for esophageal cancer. It remains controversial, whether induction radiochemotherapy before resection can improve long-term survival for esophageal cancer patients. Researches have found that preoperative treatment only increases survival rates for patients who respond to induction therapy, but not for non-responders. Therefore, to identify the predictive biomarkers for induction therapy draw much attention. Although still far from satisfactory results, some have been obtained. Here, we summarize the potential biomarker candidates for reference.
Biomarkers
;
Chemoradiotherapy
;
Esophageal Neoplasms
;
drug therapy
;
Humans
;
Neoadjuvant Therapy
;
Survival Rate
5.Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer.
Chinese Journal of Gastrointestinal Surgery 2013;16(9):805-810
The prognosis of patients with locally advanced esophageal cancer treated by surgery alone is poor. The neoadjuvant chemoradiotherapy is considered to improve the long-term survival of patients with locally advanced esophageal cancer. The combination of neoadjuvant chemoradiotherapy and surgery has been recommended to be the standard treatment for the locally advanced esophageal cancer in China even in Europe and America countries. However, available evidence suggests that only those who had histopathologic response seemed to benefit the most from neoadjuvant chemotherapy while non-responders even had rather worse outcome compared to patients with surgery alone. Therefore, predictive markers of response to neoadjuvant chemoradiotherapy in locally advanced esophageal cancer are highly significant and needed. These markers would allow a tailored treatment to guide non-responders to alternative preoperative therapies and ultimately avoid ineffective, costly and seriously cytotoxic treatments. Results of most studies on biomarkers for predicting response to neoadjuvant chemoradiotherapy in esophageal cancer are promising. The potential utilization of biomarkers in clinical practice is urgently expected and needed, which plays an important role in guiding and improving the individualization of multimodality therapy in locally advanced esophageal cancer.
Biomarkers, Tumor
;
Chemoradiotherapy
;
Esophageal Neoplasms
;
drug therapy
;
radiotherapy
;
surgery
;
Humans
;
Neoadjuvant Therapy
;
methods
;
Treatment Outcome
6.Perioperative chemotherapy improves long-term survival of esophageal cancer patients: a systemic literatures review.
Chinese Journal of Gastrointestinal Surgery 2016;19(4):477-480
The concept that peri-operative treatment could improve long-term survival of esophageal cancer patients has been universally accepted, including radiation alone, chemotherapy alone, and chemoradiation. The most controversial therapy is perioperative chemotherapy. Here we review the published literatures for reference. The result shows that perioperative chemotherapy is effective for esophageal cancer patients, especially for the so-called chemo-sensitive patients, and the preferred delivering time is before surgery. According to the current data, it is still unclear whether the efficacy of neoadjuvant chemotherapy is inferior to that of neoadjuvant chemoradiation.
Chemoradiotherapy
;
Esophageal Neoplasms
;
drug therapy
;
surgery
;
Humans
;
Neoadjuvant Therapy
;
Survival Rate
7.Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis.
Dong-Bin WANG ; Zhong-Yi SUN ; Li-Min DENG ; De-Qing ZHU ; Hong-Gang XIA ; Peng-Zhi ZHU
Chinese Medical Journal 2016;129(24):2974-2982
BACKGROUNDThe effectiveness of neoadjuvant chemoradiotherapy (NCRT) treatment for patients with esophageal carcinoma (EC) remains controversial. The aim of this study was to compare the effect of NCRT followed by surgery (NCRTS) with surgery alone (SA) for EC.
METHODSThe PubMed, EMBASE, and the Cochrane Library databases were electronically searched up to August 2015 for all the published studies that investigated EC patients receiving either NCRTS or SA, and the reference lists were also manually examined for the eligible studies. The risk ratio (RR) with 95% confidence intervals (CI s) as effective size was determined to assess the 1-, 3-, 5-year survival rates (SRs), postoperative morbidity, and postoperative mortality. Heterogeneity was determined using the Q-test. The Begg's test and Egger's test were used for assessing any potential publication bias.
RESULTSOf 1120 identified studies, 16 eligible studies were included in this analysis (involving 2549 patients). Overall, the pooled results suggested that NCRTS was associated with significantly improved 1-year (RR: 1.07, 95% CI: 1.02-1.13), 3-year (RR: 1.26, 95% CI: 1.14-1.39), and 5-year (RR: 1.36, 95% CI: 1.18-1.56) SRs. However, the results also indicated that NCRTS had no or little effect on postoperative morbidity (RR: 0.93, 95% CI: 0.82-1.05) and postoperative mortality (RR: 1.17, 95% CI: 0.56-2.44).
CONCLUSIONSCompared with SA, NCRTS can increase 1-, 3-, and 5-year SRs in patients with EC.
Chemoradiotherapy ; methods ; Esophageal Neoplasms ; drug therapy ; mortality ; Humans ; Neoadjuvant Therapy ; methods ; Survival Rate
8.Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective
Thorsten Oliver GOETZE ; Salah Eddin AL-BATRAN ; Felix BERLTH ; Arnulf Heinrich HOELSCHER
Journal of Gastric Cancer 2019;19(2):148-156
Esophagogastric junction (EGJ) cancer is a solid tumor entity with rapidly increasing incidence in the Western countries. Given the high proportion of advanced cancers in the West, treatment strategies routinely employed include surgery and chemotherapy perioperatively, and chemoradiation in neoadjuvant settings. Neoadjuvant chemoradiation and perioperative chemotherapy are mostly performed in esophageal cancer that extends to the EGJ and gastric as well as EGJ cancers, respectively. Recent trials have tried to combine both strategies in a perioperative context, which might have beneficial outcomes, especially in patients with EGJ cancer. However, it is difficult to recruit patients for trials, exclusively for EGJ cancers; therefore, the results have to be carefully reviewed before establishing a standard protocol. Trastuzumab was the first drug for targeted therapy that was positively evaluated for this tumor entity, and there are several ongoing trials investigating more targeted drugs in order to customize effective therapies based on tissue characteristics. The current study reviews the multimodal treatment concept for EGJ cancers in the West and summarizes the latest reports.
Combined Modality Therapy
;
Drug Therapy
;
Esophageal Neoplasms
;
Esophagogastric Junction
;
Humans
;
Incidence
;
Trastuzumab
9.Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy.
Yan YAN ; Xijia FENG ; Chengqiang LI ; Toni LERUT ; Hecheng LI
Chinese Medical Journal 2022;135(18):2143-2156
Esophageal cancer (EC) has a high incidence and poor prognosis. The two major histological types, squamous cell carcinoma and adenocarcinoma, differ in their epidemiology and treatment options. Patients with locally advanced EC benefit from multimodal therapy concepts including neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and perioperative chemotherapy. Currently, immunotherapy for the solid tumor is a hot spot. Treatment with adjuvant immune checkpoint inhibitors (ICIs) is the first immunotherapy for resectable EC listed in the latest National Comprehensive Cancer Network Guidelines for the Esophageal and Esophagogastric Junction Cancers. Recent clinical trials have established ICIs for three treatment models of resectable EC. Their short-term results demonstrated ideal efficacy and tolerable toxicity, though some concerns remain. This review summarizes the novel data on the ICIs for resectable EC and lists the registered related clinical trials. Hopefully, this review can provide a reference for ongoing research on the treatment options for resectable EC.
Humans
;
Esophageal Neoplasms/pathology*
;
Esophagogastric Junction/pathology*
;
Neoadjuvant Therapy/methods*
;
Adenocarcinoma/drug therapy*
;
Immunotherapy
10.Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer.
Mohan HINGORANI ; Sanjay DIXIT ; Miriam JOHNSON ; Victoria PLESTED ; Kevin ALTY ; Peter COLLEY ; Andrew W BEAVIS ; Rajarshi ROY ; Anthony MARAVEYAS
Cancer Research and Treatment 2015;47(4):706-717
PURPOSE: We report the outcomes of patients treated with palliative radiotherapy (pRT) to the primary tumour in the context of well-controlled metastatic disease after initial chemotherapy. MATERIALS AND METHODS: Clinical records of 132 patients with metastatic esophago-gastric (OG) cancer treated with palliative chemotherapy (pCT) between January 2009 and June 2013 were reviewed. Ninetyseven patients had responding or stable disease after 3 months of chemotherapy, of whom 53 patients received pRT to the primary tumour after initial chemotherapy in the presence of well-controlled metastatic disease (group A, pCT-RT). The remaining 44 patients were treated with pCT alone (group B, pCT). Treatment-related outcomes were assessed in above groups including time to local progression (TTLP), progression-free and overall survival. RESULTS: The median overall survival for patients treated with pRT after initial chemotherapy (group A) was 23.3 months (95% confidence interval [CI], 17.70 to 28.89 months) and significantly higher than the 14 months (95% CI, 10.91 to 17.08 months) in patients treated with pCT alone (group B) (p < 0.001). The use of pCT-RT was an independent predictor of OS in multivariate analysis. Local recurrence was observed in 12/53 of patients (23%) in group A compared to 16/44 (36%) in group B. The median TTLP was significantly higher in patients after pCT-RT at 17.3 months (5.23 months to 44.50 months) compared to 8.3 months (range, 4.10 to 25.23 months) in patients treated with pCT alone (p=0.006). CONCLUSION: The possibility of pRT influencing systemic disease in advanced OG cancer has not been reported, and results from the present study present strong arguments for investigation of this therapeutic strategy in a randomized trial.
Drug Therapy*
;
Esophageal Neoplasms
;
Humans
;
Multivariate Analysis
;
Palliative Care
;
Radiotherapy*
;
Recurrence
;
Stomach Neoplasms*